Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYR-210 for Chronic Rhinosinusitis (ENLIGHTEN 2)
NCT05295459Phase 3Completed
- Sponsor
- Lyra Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Polymer-based Nanoparticles, Device-based Delivery, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of LYR-210 in chronic rhinosinusitis (CRS), sponsored by Lyra Therapeutics, Inc.. Started May 2022; status: completed.
02
Drugs
LYR-210
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT05295459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295459.